接口广告
摩熵化学
数据开放平台 数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4-Methylpiperazin-1-yl)-(oxolan-2-yl)methanone | 560097-65-6

中文名称
——
中文别名
——
英文名称
(4-Methylpiperazin-1-yl)-(oxolan-2-yl)methanone
英文别名
——
(4-Methylpiperazin-1-yl)-(oxolan-2-yl)methanone化学式
CAS
560097-65-6
化学式
C10H18N2O2
mdl
MFCD03384288
分子量
198.26
InChiKey
ZSHARPJAQXGCMB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    32.8
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINES COMME INHIBITEURS DE LA KINASE RET
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2017011776A1
    公开(公告)日:2017-01-19
    Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    本文提供了一般式I的化合物及其立体异构体和药用可接受的盐或溶剂,其中A、B、D、E、X1、X2、X3和X4的含义如规范中所述,这些化合物是RET激酶的抑制剂,可用于治疗和预防可以用RET激酶抑制剂治疗的疾病,包括由RET激酶介导的疾病或紊乱。
  • [EN] DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS<br/>[FR] COMPOSÉS D'INDOLE SUBSTITUÉS PAR DU DIMÉTHOXYPHÉNYLE COMME DES INHIBITEURS DE TLR7, TLR8 OU TLR9
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2018026620A1
    公开(公告)日:2018-02-08
    Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    揭示了Formula (I)或其盐的化合物,其中R1、R3、R4、R5、m和n在此处被定义。还揭示了使用这些化合物作为Toll样受体7、8或9信号传导抑制剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗炎症性和自身免疫疾病方面是有用的。
  • TRICYCLIC GYRASE INHIBITORS
    申请人:Bensen Daniel
    公开号:US20120238751A1
    公开(公告)日:2012-09-20
    Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.
    本文披露了具有式I结构的化合物,以及作为抗菌有效的三环抑制剂的药用盐、酯和前药,相关的药物组合物、用途和制备该化合物的方法也在考虑之中。
  • [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRAZINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
    申请人:ANDREWS STEVEN W
    公开号:WO2018136661A1
    公开(公告)日:2018-07-26
    Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    本文提供了Formula I的化合物及其立体异构体和药学上可接受的盐或溶剂,其中A、B、D、E、X1、X2、X3和X4在规范中给出的含义,这些化合物是RET激酶的抑制剂,可用于治疗和预防可以用RET激酶抑制剂治疗的疾病,包括由RET激酶介导的疾病或紊乱。
  • [EN] NOVEL IMMUNE SYSTEM MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU SYSTÈME IMMUNITAIRE
    申请人:JANUS BIOTHERAPEUTICS INC
    公开号:WO2012167053A1
    公开(公告)日:2012-12-06
    The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.
    本发明涉及一种化合物,其化学式如下:或其药用盐,其中符号如规范中定义;包含该化合物的药物组合物;以及使用该化合物治疗或预防自身免疫疾病的方法。
查看更多